RAD001
CRAD001M2304
Phase 3 small_molecule completed
Quick answer
RAD001 for Tuberous Sclerosis Complex-associated Refractory Seizures is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Tuberous Sclerosis Complex-associated Refractory Seizures
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed